Rodríguez J C, Díaz M, González L O, Sánchez J, Sánchez M T, Merino A M, Vizoso F
Servicio de Cirugía General Hospital de Jove, Avda. Eduardo Castro s/n 33290 Gijón, Spain.
Int J Surg Investig. 2000;2(4):319-26.
Apolipoprotein D (ApoD), a protein component of the human plasma lipid transport system, is an androgen regulated protein in both breast and prostate cancer cell lines.
Here we examined, by immunohistochemical assay, the ApoD expression in normal, benign and malignant prostate tissues.
ApoD was detected in the two analyzed normal prostate tissues, in 16 (94.1%) of 17 benign prostatic hyperplasias, and in 36 (63.1%) of 57 prostate carcinomas. In prostate carcinomas, ApoD immunostaining values did not show significant relationship neither with age of the patients, stage and histologic grade of the tumors, nor with preoperative serum levels of prostatic specific antigen (PSA). However, ApoD-negative immunostaining predicted shorter survival duration in the subgroup of 46 patients with nonresectable prostate cancer (p = 0.02).
Our results led us to consider that Apo D expression by prostate carcinomas migth be of clinical usefulness for identificating lesions with different evolution.
载脂蛋白D(ApoD)是人类血浆脂质转运系统的一种蛋白质成分,在乳腺癌和前列腺癌细胞系中均为雄激素调节蛋白。
在此,我们通过免疫组织化学检测,研究了正常、良性和恶性前列腺组织中ApoD的表达情况。
在两个分析的正常前列腺组织、17例良性前列腺增生中的16例(94.1%)以及57例前列腺癌中的36例(63.1%)中检测到了ApoD。在前列腺癌中,ApoD免疫染色值与患者年龄、肿瘤分期和组织学分级均无显著关系,也与术前血清前列腺特异性抗原(PSA)水平无关。然而,在46例不可切除前列腺癌患者亚组中,ApoD阴性免疫染色预示着生存期较短(p = 0.02)。
我们的结果使我们认为,前列腺癌中ApoD的表达可能对鉴别具有不同进展的病变具有临床意义。